Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Richard Philip Grose

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4738-0173; OpenAlex author ID A5047857642. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 10

  1. Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". Co-author DOI 10.1016/j.jpet.2026.104305↗
  2. Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jpet.2025.103573↗
  3. AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. Co-author DOI 10.1038/s41598-025-87337-5↗
  4. Ephrin inhibition disrupts stromal-cancer crosstalk and reduces metastasis in pancreatic cancer Last author DOI 10.64898/2025.12.10.693406↗
  5. Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. Last author DOI 10.7554/elife.86971↗
  6. Pancreatic Cancer Organotypic Models. First author DOI 10.1007/82_2019_155↗
  7. Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. Last author DOI 10.3390/cells10040847↗
  8. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. Co-author DOI 10.1002/path.4727↗
  9. Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-16-0481↗
  10. Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion. Last author DOI 10.1002/emmm.201302698↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hemant Mahendrakumar Kocher · 7 shared papers, 2014–2025 · strength 0.96
  2. Elena Tomás Bort · 4 shared papers, 2021–2026 · strength 0.82
  3. Peter James McCormick · 3 shared papers, 2023–2026 · strength 0.66
  4. Edward P. Carter · 3 shared papers, 2021–2025 · strength 0.55
  5. Paul A. Insel · 2 shared papers, 2025–2026 · strength 0.49
  6. Krishna Sriram · 2 shared papers, 2025–2026 · strength 0.49
  7. Cristina Salmerón · 2 shared papers, 2025–2026 · strength 0.49
  8. Jonathan Weitz · 2 shared papers, 2025–2026 · strength 0.49
  9. Andrew M. Lowy · 2 shared papers, 2025–2026 · strength 0.49
  10. Hervé Tiriac · 2 shared papers, 2025–2026 · strength 0.49
  11. Abigail S. Coetzee · 2 shared papers, 2021 · strength 0.38
  12. Claude Chelala · 2 shared papers, 2016–2025 · strength 0.31
  13. Mohamed Zardab · 1 shared paper, 2025 · strength 0.26
  14. Christine Hughes · 1 shared paper, 2025 · strength 0.26
  15. Barts Pancreas Tissue Bank · 1 shared paper, 2025 · strength 0.26
  16. Shinelle Menezes · 1 shared paper, 2025 · strength 0.22
  17. Angus J.M. Cameron · 1 shared paper, 2025 · strength 0.22
  18. Cerian L. Bolton · 1 shared paper, 2025 · strength 0.22
  19. Guillem Fuertes · 1 shared paper, 2025 · strength 0.22
  20. John F. Marshall · 1 shared paper, 2025 · strength 0.22
  21. Joshua B.N. Dawkins · 1 shared paper, 2016 · strength 0.05
  22. Eleni Maniati · 1 shared paper, 2016 · strength 0.05
  23. Jun Wang · 1 shared paper, 2016 · strength 0.05
  24. Elisabete Carapuça · 1 shared paper, 2016 · strength 0.05
  25. Tashinga E. Bapiro · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.